 |
 |
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
20 June 2000 | Volume 132 Issue 12 | Pages 947-954
Background: Lung inflammation (alveolitis) may cause lung fibrosis in scleroderma.
Objective: To determine whether cyclophosphamide treatment is associated with retention of lung function and improved survival in scleroderma patients with alveolitis.
Design: Retrospective cohort study.
Setting: Johns Hopkins and University of Maryland Scleroderma Center.
Patients: 103 patients with scleroderma who had bronchoalveolar lavage or lung biopsy.
Intervention: Cyclophosphamide therapy.
Measurements: 1) Serial measurement of forced vital capacity [FVC] and carbon monoxide diffusing capacity and 2) survival.
Results: During a median follow-up of 13 months after bronchoalveolar lavage or biopsy, patients with alveolitis who did not receive cyclophosphamide therapy experienced a decrease in FVC (mean difference, –0.28 L [95% CI, –0.41 to –0.16 L] and –7.1% of the predicted value [CI, –10.9% to –4.0%]). Carbon monoxide diffusing capacity also decreased in these patients (mean difference, –3.3 mmol · min – 1 · kPa – 1 [CI, –4.6 to –2.1 mmol · min – 1 ·kPa – 1] and –9.6% of the predicted value [CI, –16.7% to –2.4%]). During a median follow-up of 16 months, patients with alveolitis who received cyclophosphamide were more likely to have a good outcome (stabilization or improvement) in FVC (relative risk, 2.5 [CI, 1.5 to 4.1]) and diffusing capacity (relative risk, 1.5 [CI, 1.0 to 2.2]). These patients also had improved survival; the median survival rate was 89% (25th, 75th percentiles, 84%, 94%) compared with 71% (25th, 75th percentiles, 55%, 86%) in untreated patients (P = 0.01, log-rank test).
Conclusions: The presence of lung inflammation identifies patients with scleroderma who are more likely to have worsening lung function. Lung function outcomes and survival are improved in patients with alveolitis who receive cyclophosphamide.
Author and Article Information
From Veterans Affairs Maryland Health Care System, University of Maryland School of Medicine, and Johns Hopkins University Medical Institutions, Baltimore, Maryland.
Grant Support: By grant 1RO1HL54163 from the National Institutes of Health (Dr. White) and a grant from the Maryland Chapter, Arthritis Foundation.
Requests for Single Reprints: Barbara White, MD, Baltimore Veterans Affairs Medical Center, Research Service, Stop 151, Room 325-A, 10 North Greene, Baltimore, MD 21201.
Requests To Purchase Bulk Reprints (minimum, 100 copies): the Reprints Coordinator; phone, 215-351-2657; e-mail, reprints{at}mail.acponline.org.
Current Author Addresses: Dr. White: Baltimore Veterans Affairs Medical Center, Research Service, Stop 151, Room 3A-125, 10 North Greene Street, Baltimore, MD 21201.
Dr. Moore: Division of Pulmonary and Critical Care Medicine, Biomedical Research Building, 108 North Greene Street, Suite 119, Baltimore, MD 21201.
Dr. Wigley: Division of Molecular and Clinical Rheumatology, Johns Hopkins University School of Medicine, 1830 East Monument Street, Suite 7300, Baltimore, MD 21205.
Drs. Xiao and Wise: Division of Pulmonary and Critical Care Medicine, Johns Hopkins University School of Medicine, 5501 Hopkins Bayview Circle, Room 4B-72, Baltimore, MD 21224.
Author Contributions: Conception and design: B. White, F.M. Wigley, R.A. Wise.
Analysis and interpretation of the data: B. White, F.M. Wigley, R.A. Wise.
Drafting of the article: B. White, W.C. Moore.
Critical revision of the article for important intellectual content: B. White, F.M. Wigley, R.A. Wise.
Final approval of the article: B. White, W.C. Moore, F.M. Wigley, H.Q. Xiao, R.A. Wise.
Provision of study materials or patients: B. White, F.M. Wigley, R.A. Wise.
Statistical expertise: R.A. Wise.
Obtaining of funding: B. White.
Administrative, technical, or logistic support: B. White, F.M. Wigley.
Collection and assembly of data: B. White, W.C. Moore, H.Q. Xiao, R.A. Wise. ARTICLE
Cyclophosphamide Is Associated with Pulmonary Function and Survival Benefit in Patients with Scleroderma and Alveolitis
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  I. Sabnani, M. J. Zucker, E. D. Rosenstein, D. A. Baran, L. H. Arroyo, P. Tsang, M. Zubair, and V. Rivera A novel therapeutic approach to the treatment of scleroderma-associated pulmonary complications: safety and efficacy of combination therapy with imatinib and cyclophosphamide Rheumatology, January 1, 2009; 48(1): 49 - 52. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Khanna, D. E. Furst, P. J. Clements, D. P. Tashkin, and M. H. Eckman Oral Cyclophosphamide for Active Scleroderma Lung Disease: A Decision Analysis Med Decis Making, November 1, 2008; 28(6): 926 - 937. [Abstract] [PDF]
|
|
|
|
 |
|
 A U Wells, N Hirani, and on behalf of the BTS Interstitial Lung Disease Gui Interstitial lung disease guideline Thorax, September 1, 2008; 63(Suppl_5): v1 - v58. [Full Text] [PDF]
|
|
|
|
 |
|
 J. G. Goldin, D. A. Lynch, D. C. Strollo, R. D. Suh, D. E. Schraufnagel, P. J. Clements, R. M. Elashoff, D. E. Furst, S. Vasunilashorn, M. F. McNitt-Gray, et al. High-Resolution CT Scan Findings in Patients With Symptomatic Scleroderma-Related Interstitial Lung Disease Chest, August 1, 2008; 134(2): 358 - 367. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Strange and J. R. Seibold Scleroderma Lung Disease: "If You Don't Know Where You Are Going, Any Road Will Take You There" Am. J. Respir. Crit. Care Med., June 1, 2008; 177(11): 1178 - 1179. [Full Text] [PDF]
|
|
|
|
|
|
A. J. Gerbino, C. H. Goss, and J. A. Molitor Effect of Mycophenolate Mofetil on Pulmonary Function in Scleroderma-Associated Interstitial Lung Disease Chest, February 1, 2008; 133(2): 455 - 460. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. P. Baughman and G. Raghu Bronchoalveolar Cellular Analysis in Scleroderma Lung Disease: Does Sutton's Law Hold? Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 2 - 3. [Full Text] [PDF]
|
|
|
|
|
|
C. Strange, M. B. Bolster, M. D. Roth, R. M. Silver, A. Theodore, J. Goldin, P. Clements, J. Chung, R. M. Elashoff, R. Suh, et al. Bronchoalveolar Lavage and Response to Cyclophosphamide in Scleroderma Interstitial Lung Disease Am. J. Respir. Crit. Care Med., January 1, 2008; 177(1): 91 - 98. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. J Clements, M. D Roth, R. Elashoff, D. P Tashkin, J. Goldin, R. M Silver, M. Sterz, J. R Seibold, D. Schraufnagel, R. W Simms, et al. Scleroderma lung study (SLS): differences in the presentation and course of patients with limited versus diffuse systemic sclerosis Ann Rheum Dis, December 1, 2007; 66(12): 1641 - 1647. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. P. Tashkin, R. Elashoff, P. J. Clements, M. D. Roth, D. E. Furst, R. M. Silver, J. Goldin, E. Arriola, C. Strange, M. B. Bolster, et al. Effects of 1-Year Treatment with Cyclophosphamide on Outcomes at 2 Years in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., November 15, 2007; 176(10): 1026 - 1034. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. A. Feghali-Bostwick, C. G. Tsai, V. G. Valentine, S. Kantrow, M. W. Stoner, J. M. Pilewski, A. Gadgil, M. P. George, K. F. Gibson, A. M. K. Choi, et al. Cellular and Humoral Autoreactivity in Idiopathic Pulmonary Fibrosis J. Immunol., August 15, 2007; 179(4): 2592 - 2599. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. Verrecchia, J. Laboureau, O. Verola, N. Roos, R. Porcher, P. Bruneval, M. Ertault, K. Tiev, L. Michel, A. Mauviel, et al. Skin involvement in scleroderma--where histological and clinical scores meet Rheumatology, May 1, 2007; 46(5): 833 - 841. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. J. Swigris, A. L. Olson, A. Fischer, D. A. Lynch, G. P. Cosgrove, S. K. Frankel, R. T. Meehan, and K. K. Brown Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease. Chest, July 1, 2006; 130(1): 30 - 36. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
O. Sanchez, O. Sitbon, X. Jais, G. Simonneau, and M. Humbert Immunosuppressive therapy in connective tissue diseases-associated pulmonary arterial hypertension. Chest, July 1, 2006; 130(1): 182 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. P. Tashkin, R. Elashoff, P. J. Clements, J. Goldin, M. D. Roth, D. E. Furst, E. Arriola, R. Silver, C. Strange, M. Bolster, et al. Cyclophosphamide versus placebo in scleroderma lung disease. N. Engl. J. Med., June 22, 2006; 354(25): 2655 - 2666. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. J. Martinez and W. J. McCune Cyclophosphamide for scleroderma lung disease. N. Engl. J. Med., June 22, 2006; 354(25): 2707 - 2709. [Full Text] [PDF]
|
|
|
|
|
|
V Steen Predictors of end stage lung disease in systemic sclerosis Ann Rheum Dis, February 1, 2003; 62(2): 97 - 99. [Full Text] [PDF]
|
|
|
|
 |
|
 P. A. McSweeney, R. A. Nash, K. M. Sullivan, J. Storek, L. J. Crofford, R. Dansey, M. D. Mayes, K. T. McDonagh, J. L. Nelson, T. A. Gooley, et al. High-dose immunosuppressive therapy for severe systemic sclerosis: initial outcomes Blood, August 13, 2002; 100(5): 1602 - 1610. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. G. Crystal, P. B. Bitterman, B. Mossman, M. I. Schwarz, D. Sheppard, L. Almasy, H. A. Chapman, S. L. Friedman, T. E. King Jr., L. A. Leinwand, et al. Future Research Directions in Idiopathic Pulmonary Fibrosis: Summary of a National Heart, Lung, and Blood Institute Working Group Am. J. Respir. Crit. Care Med., July 15, 2002; 166(2): 236 - 246. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Bouros, A. U. Wells, A. G. Nicholson, T. V. Colby, V. Polychronopoulos, P. Pantelidis, P. L. Haslam, D. A. Vassilakis, C. M. Black, and R. M. du Bois Histopathologic Subsets of Fibrosing Alveolitis in Patients with Systemic Sclerosis and Their Relationship to Outcome Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1581 - 1586. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. E. Girgis, M. K. Gugnani, J. Abrams, and M. D. Mayes Partitioning of Alveolar and Conducting Airway Nitric Oxide in Scleroderma Lung Disease Am. J. Respir. Crit. Care Med., June 15, 2002; 165(12): 1587 - 1591. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. G. Luzina, S. P. Atamas, R. Wise, F. M. Wigley, H. Q. Xiao, and B. White Gene Expression in Bronchoalveolar Lavage Cells from Scleroderma Patients Am. J. Respir. Cell Mol. Biol., May 1, 2002; 26(5): 549 - 557. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. K. Burt, S. Slavin, W. H. Burns, and A. M. Marmont Induction of tolerance in autoimmune diseases by hematopoietic stem cell transplantation: getting closer to a cure? Blood, February 1, 2002; 99(3): 768 - 784. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. N. Sapadin and R. Fleischmajer Treatment of Scleroderma Arch Dermatol, January 1, 2002; 138(1): 99 - 105. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Cyclophosphamide May Provide Benefit in Scleroderma Journal Watch Dermatology, August 1, 2000; 2000(801): 14 - 14. [Full Text]
|
|
|
|
 |
|
 Cyclophosphamide May Provide Benefit in Scleroderma Journal Watch (General), June 30, 2000; 2000(630): 4 - 4. [Full Text]
|
|
Article
